CBP501
Platinum-resistant ovarian cancer, Mesothelioma
Phase 2Active
Key Facts
About CanBas
Japanese oncology biotech developing small molecule DNA damage response inhibitors to enhance cancer treatment efficacy.
View full company profilePlatinum-resistant ovarian cancer, Mesothelioma
Japanese oncology biotech developing small molecule DNA damage response inhibitors to enhance cancer treatment efficacy.
View full company profile